US4037831033 - Common Stock
GYRE THERAPEUTICS INC
NASDAQ:GYRE (5/17/2024, 7:03:18 PM)
14.24
-1.05 (-6.87%)
Gyre Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2006-04-12. Gyre Therapeutics, Inc., formerly Catalyst Biosciences, Inc., is a biotechnology company. The firm is focused on organ fibrosis and inflammatory diseases. The firm is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The firm is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase 3 trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase 1 trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.
GYRE THERAPEUTICS INC
12770 High Bluff Drive, Suite 150
San Diego CALIFORNIA
P: 16199493681
Employees: 7
Website: https://www.gyretx.com/
Gyre Therapeutics just reported results for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gyre Therapeutics (NASDAQ:GYRE) just reported results for the first quarter of ...
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update...
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.
Here you can normally see the latest stock twits on GYRE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: